Beijing Luzhu Biotechnology Co (HKSE:02480) EBITDA Margin % : 0.00% (As of Jun. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Beijing Luzhu Biotechnology Co EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Beijing Luzhu Biotechnology Co's EBITDA for the six months ended in Jun. 2023 was HK$-86.37 Mil. Beijing Luzhu Biotechnology Co's Revenue for the six months ended in Jun. 2023 was HK$0.00 Mil. Therefore, Beijing Luzhu Biotechnology Co's EBITDA margin for the quarter that ended in Jun. 2023 was 0.00%.

Beijing Luzhu Biotechnology Co EBITDA Margin % Historical Data

The historical data trend for Beijing Luzhu Biotechnology Co's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Luzhu Biotechnology Co EBITDA Margin % Chart

Beijing Luzhu Biotechnology Co Annual Data

Trend

Dec21

Dec22

Dec23

EBITDA Margin %

Beijing Luzhu Biotechnology Co Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
EBITDA Margin %	-	-	-	-	-

Competitive Comparison of Beijing Luzhu Biotechnology Co's EBITDA Margin %

For the Biotechnology subindustry, Beijing Luzhu Biotechnology Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beijing Luzhu Biotechnology Co's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beijing Luzhu Biotechnology Co's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Beijing Luzhu Biotechnology Co's EBITDA Margin % falls into.

Beijing Luzhu Biotechnology Co EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Beijing Luzhu Biotechnology Co's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-797.975	/	0
	=	%

Beijing Luzhu Biotechnology Co's EBITDA Margin % for the quarter that ended in Jun. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-86.371	/	0
	=	%

Beijing Luzhu Biotechnology Co (HKSE:02480) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Beijing Luzhu Biotechnology Co EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Beijing Luzhu Biotechnology Co's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Beijing Luzhu Biotechnology Co (HKSE:02480) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Luzhu Biotechnology Co Ltd (HKSE:02480) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 Guangtong Street, Industrial Development Zone, Zhangjiawan Tongzhou District, Beijing, CHN

Website

http://www.luzhubiotech.com

Beijing Luzhu Biotechnology Co Ltd is a biotechnology company committed to developing innovative human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. Its clinical-stage product candidates comprise one vaccine candidate, LZ901 and two antibody injection product candidates, including K3 and K193. LZ901 is our Core Product.

Executives

Ma Jianan	2201 Interest of corporation controlled by you
Zhu Hai Heng Qin Lv Zhu Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Bei Jing Lv Zhu Kang Rui Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Bei Jing Sai Sheng Yao Ye Gu Fen You Xian Gong Si	2101 Beneficial owner
Bei Jing Yi Zhuang Er Qi Sheng Wu Yi Yao Chan Ye Tou Zi Ji Jin You Xian He Huo	2101 Beneficial owner
Bei Jing Yi Zhuang Sheng Wu Yi Yao Bing Gou Tou Zi Zhong Xin You Xian He Huo	2101 Beneficial owner
Tian Jin Sai Ding Fang De Zi Chan Guan Li Zhong Xin	2201 Interest of corporation controlled by you
Tian Jin Sai De Rui Bo Zi Chan Guan Li Zhong Xin	2201 Interest of corporation controlled by you
Bei Jing Yi Tang Sai Ying Ji Jin Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
China Construction Bank Corporation	2201 Interest of corporation controlled by you
Central Huijin Investment Ltd.	2201 Interest of corporation controlled by you
Peng Ling	2201 Interest of corporation controlled by you
Zhang Yanping	2202 Interest of your spouse
Kong Jian	2101 Beneficial owner
Ma Biao	2201 Interest of corporation controlled by you

Beijing Luzhu Biotechnology Co (HKSE:02480) Headlines

No Headlines